Available Until 4/9/2024
View Cart

Infectious Diseases Pharmacy Specialty Recertification Literature Study: Module 1A-B (Cert # L239192)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 03/15/2023
Content Release Date: 04/12/2023
Expiration Dates: 04/09/2024
Activity Type: Application-based
CE Credits: 8 contact hours (BPS and ACPE)
Activity Fee: $55 (ASHP member); $110 (non-member)

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice. 

Module 1A: Gram-Negative Infections and Fever of Unknown Origin -- This module focuses on treatment of antimicrobial resistant gram-negative infections and fever of unknown origin. 

Module 1B: Update in Infectious Diseases Topics -- This module focuses on various topics including treatment duration, management of cryptococcal meningitis and Clostridioides difficile, and tele-antimicrobial stewardship programs.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP professional development program for BCIDP recertification approved by the BPS. 

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

  

    

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification contact hours through the Board of Pharmacy Specialties (BPS).

Board certified pharmacists are eligible to receive up to 8 contact hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete these assessments.

Learning Activity

ACPE Number

Contact Hours (ACPE and BPS)

Assessment Pass Point

Infectious Diseases Pharmacy Specialty Recertification Literature Study Module 1A: Gram-Negative Infections and Fever of Unknown Origin

0204-9999-23-960-H01-P

3.0

 80%

Infectious Diseases Pharmacy Specialty Recertification Literature Study Module 1B: Update in Infectious Diseases Topics

0204-9999-23-961-H01-P

5.0

 72%

Module 1A: Gram-Negative Infections and Fever of Unknown Origin
ACPE Number: 0204-9999-23-960-H01

This module focuses on treatment of antimicrobial resistant Gram-negative infections and fever of unknown origin.

Tamma PD, Aitken SL, Bonomo RA et al. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022; 74(12):2089-2114.

Learning Objectives:

  • Describe the Infectious Diseases Society of America (IDSA) guidance on the treatment of AmpC β-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia (S. maltophilia) infections
  • Develop recommendations for the treatment of infections caused by AmpC β-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Acinetobacter baumannii (CRAB), or Stenotrophomonas maltophilia (S. maltophilia)

Sarzynski SH, Warner S, Sun J et al. Trimethoprim-sulfamethoxazole versus levofloxacin for Stenotrophomonas maltophilia infections: a retrospective comparative effectiveness study of electronic health records from 154 US hospitals. Open Forum Infect Dis. 2022; 9(2):ofab644.

Learning Objectives:

  • Describe the study by Sarzynski and colleagues comparing trimethoprim-sulfamethoxazole (TMP-SMX) with levofloxacin for the treatment of bloodstream or lower respiratory tract infection caused by Stenotrophomonas maltophilia
  • Develop antibiotic therapy recommendations for adults hospitalized with bloodstream or lower respiratory tract infection caused by Stenotrophomonas maltophilia

Haidar G, Singh N. Fever of unknown origin. N Engl J Med. 2022; 386:463-477.

Learning Objectives:

  • Describe the febrile response and etiology, diagnosis, and management of fever of unknown origin (FUO)
  • Develop recommendations for the diagnostic work up and management of patients with fever of unknown origin (FUO)

Module 1B: Update in Infectious Diseases Topics
ACPE Number: 0204-9999-23-961-H01

This module focuses on various topics including treatment duration, management of cryptococcal meningitis and Clostridioides difficile, and tele-antimicrobial stewardship programs. 

Drekonja DM, Trautner B, Amundson C et al. Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a randomized clinical trial. JAMA. 2021; 326(4):324-331. 

Learning Objectives:

  • Describe the study by Drekonja and colleagues evaluating the resolution of urinary tract infection symptoms in afebrile men from the use of 7 days or 14 days of antibiotic therapy
  • Develop recommendations for the duration of antibiotic therapy for adult men with urinary tract infection 

Bielicki JA, Stohr W, Barratt S et al. Effect of amoxicillin dose and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia: the CAP-IT randomized clinical trial. JAMA. 2021; 326(17):1713-1724. 

Learning Objectives:

  • Describe the CAP-IT trial by Bielicki and colleagues of the effect of amoxicillin dosage and treatment duration on the need for antibiotic re-treatment in children with community-acquired pneumonia (CAP)
  • Develop recommendations for the dosage and duration of treatment with amoxicillin of young children with community-acquired pneumonia (CAP) 

Jarvis JN, Lawrence DS, Meya DB et al.Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. N Engl J Med. 2022; 386(12):1109-1120. 

Learning Objectives:

  • Describe the Ambition trial by Jarvis and colleagues of liposomal amphotericin B treatment for cryptococcal meningitis
  • Develop recommendations for the use of liposomal amphotericin B in human immunodeficiency virus (HIV)-positive adults with cryptococcal meningitis 

Johnson S, Lavergne V, Skinner AM et al.  Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021; 73(5):e1029-e1044. 

Learning Objectives:

  • Describe the clinical practice guideline with a 2021 focused update from the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America on the management of Clostridioides difficile infection in adults
  • Develop recommendations for the management of Clostridioides difficile infection in adults 

Andrzejewski C, McCreary EK, Khadem T et al. Tele-antimicrobial stewardship programs: a review of the literature and the role of the pharmacist. J Am Coll Clin Pharm. 2021; 4(8):1016-1033. 

Learning Objectives:

  • Describe challenges faced by hospitals in providing antimicrobial stewardship and models for inpatient tele-antimicrobial stewardship programs (TASPs)
  • Develop recommendations for an inpatient tele-antimicrobial stewardship program (TASP)

Full Faculty Bios

Travis J. Carlson, PharmD, BCIDP
Assistant Professor of Clinical Sciences
High Point University
Fred Wilson School of Pharmacy
High Point, North Carolina 

Kevin W. Garey, PharmD, MS, FASHP*
Professor and Chair
University of Houston
Houston, Texas 

Sarah B. Green,PharmD, BCPS, BCIDP, AAHIVP
Clinical Pharmacy Specialist, Infectious Diseases
Emory University Hospital
Atlanta, Georgia 

Jerika Lam, PharmD, APh, AAHIVP, FCSHP*
Associate Professor of Pharmacy Practice
Chapman University School of Pharmacy
Irvine, California 

Misty Miller, PharmD, BCPS, AAHIVP
Associate Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma 

Jessica Robinson, PharmD, BCPS, BCIDP
Associate Professor / Associate Director of Antimicrobial Stewardship
University of Charleston School of Pharmacy / Charleston Area Medical Center
Charleston, West Virginia 

Kayla R. Stover, PharmD, BCPS, BCIDP, FCCP, FIDSA*
Professor of Pharmacy Practice
University of Mississippi School of Pharmacy
Jackson, Mississippi 

Evan Zasowski, PharmD, MPH, BCIDP, BCPS*
Assistant Professor
Touro University California College of Pharmacy
Vallejo, California 

* Content Matter Experts

Susan R. Dombrowski, MS, RPh
Kristi Hofer, PharmD

Hakeem Abayomi, BS, PharmD, BCPS, BCPPS, BCIDP, BCCCP
Jill Argotsinger, PharmD, BCIDP
Linette Beers, PharmD
Jordan Chiasson, PharmD, BCIDP
Philip Chung, PharmD, MS, BCPS, BCIDP
Jessica  Cottreau, PharmD, BCPS
Marco Custodio, PharmD, MS, BCIDP, AAHIVP
Melissa  Danek , PharmD, BCPS, BCIDP
Alaina DeKerlegand, PharmD, BCIDP
Zach DeLanoit, PharmD, BCIDP
Alex Dominguez, PharmD, MAS, BCPS, BCIDP
Jessica Foley, PharmD, BCIDP
Mercedes Fraga, PharmD, BCPS, BCIDP, BCCCP
Lawahidh Hasham, PharmD
James Hughes, PharmD, BCPS, BCIDP
Judith Ikwuagwu, BS, PharmD, BCPS, BCIDP
Caroline Jozefczyk, PharmD, BCIDP
Meghan Kamath, PharmD, BCIDP
Bronagh  Keane, RPh, BCPS, BCID
Michael Kent, PharmD, BCIDP
Brett  Keskes, PharmD, BCIDP
Julia Kufel, PharmD, BCIDP
Jamie Legaspi, PharmD, BCIDP
Adrienne Ma, PharmD, BCIDP
Neha  Manchandia, PharmD, BCIDP
Kassandra Marsh, PharmD
Jessica Michal, PharmD, BCIDP, AAHIVP
Jessica Miller, PharmD, BCIDP
Sarah Moore, PharmD, BCIDP
Mandee Noval, PharmD, BCIDP
Sonal Patel, PharmD, BCIDP
Anna Poston-Blahnik, PharmD, BCIDP, AAHIVP
Yinghui  Pu, PharmD, PhD, BCPS, BCIDP
Alanna Rufe, PharmD, BCIDP
Julia Sapozhnikov, PharmD, BCIDP
Punit Shah, BCPS, BCIDP
Stephanie Shulder, PharmD, BCIDP
Andrea Simon, PharmD, BCIDP
Jessica Sobnosky, PharmD, BCPS, BCIDP
Kady Stoyanov, PharmD, BCIDP
Caroline Taazieh , PharmD, BCPS, BCCCP, BCIDP, BCCP
Jessica Thompson, PharmD, BCPS, BCIDP
Natalie Tucker, PharmD, BCPS, BCIDP
Obioma Ubaka , BCPS, BCIDP
Amber Welborn, PharmD, BCIDP, AAHIVP
Solomon Winans, PharmD, BCIDP
Linda Yang, PharmD, BCIDP
Min Zhang, PharmD, BCPS, BCIDP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships: 

Sarah Green: Merck & Co., Inc., research grant 

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

ASHP and ACCP collaborate on infectious diseases activities.